These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 34046083)
21. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330 [TBL] [Abstract][Full Text] [Related]
22. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505 [TBL] [Abstract][Full Text] [Related]
23. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease. Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ; J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772 [TBL] [Abstract][Full Text] [Related]
24. Biosimilar biological drugs in the treatment of inflammatory bowel diseases. Kaniewska M; Eder P; Gąsiorowska A; Gonciarz M; Kierkuś J; Małecka-Panas E; Rydzewska G Prz Gastroenterol; 2019; 14(4):223-227. PubMed ID: 31988667 [TBL] [Abstract][Full Text] [Related]
25. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Jacobs I; Singh E; Sewell KL; Al-Sabbagh A; Shane LG Patient Prefer Adherence; 2016; 10():937-48. PubMed ID: 27307714 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
27. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Chang S; Hanauer S Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249 [TBL] [Abstract][Full Text] [Related]
29. The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics. Limdi JK; Farraye FA Crohns Colitis 360; 2021 Jul; 3(3):otab015. PubMed ID: 36776664 [TBL] [Abstract][Full Text] [Related]
30. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
31. Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices. Bhat S; Qazi T Crohns Colitis 360; 2021 Jan; 3(1):otaa093. PubMed ID: 36777069 [TBL] [Abstract][Full Text] [Related]
32. Progress with infliximab biosimilars for inflammatory bowel disease. Kurti Z; Gonczi L; Lakatos PL Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797 [TBL] [Abstract][Full Text] [Related]
33. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. Danese S; Fiorino G; Michetti P J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477 [TBL] [Abstract][Full Text] [Related]
34. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. Danese S; Fiorino G; Michetti P J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706 [TBL] [Abstract][Full Text] [Related]
35. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. Armuzzi A; Avedano L; Greveson K; Kang T J Crohns Colitis; 2019 Feb; 13(2):259-266. PubMed ID: 30285235 [TBL] [Abstract][Full Text] [Related]
37. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System? Gonczi L; Ilias A; Kurti Z; Lakatos PL Curr Pharm Des; 2019; 25(1):13-18. PubMed ID: 30864504 [TBL] [Abstract][Full Text] [Related]
38. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Milassin Á; Fábián A; Molnár T Therap Adv Gastroenterol; 2019; 12():1756284819842748. PubMed ID: 31019554 [TBL] [Abstract][Full Text] [Related]
39. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. Najeeb H; Yasmin F; Surani S World J Clin Cases; 2022 May; 10(14):4327-4333. PubMed ID: 35663066 [TBL] [Abstract][Full Text] [Related]